查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405789

粗針穿刺切片市場規模、佔有率、趨勢分析報告：按技術、最終用途、地區、細分市場預測，2023-2030 年

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

乳癌粗針穿刺切片市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球粗針穿刺切片市場預計將達到11.5億美元。

預計2023年至2030年該市場將以4.9%的複合年成長率成長。推動市場成長的主要因素是乳癌盛行率的增加、定期乳房X光檢查的廣泛普及、個人意識的提高以及在該領域進行的廣泛研究。這些因素共同促進了粗針穿刺切片的需求和採用不斷增加，為未來幾年的顯著成長鋪平了道路。

此外，影像和切片檢查技術的不斷進步也促進了該行業的擴張。人們越來越認知到早期檢測和診斷在改善患者預後方面發揮的重要作用。與傳統的開放性手術切片檢查相比，粗針穿刺切片具有明顯的優勢，包括侵入性更小、恢復時間更快和成本效益高。

隨著早期檢測和診斷的需求持續上升，粗針穿刺切片市場預計將顯著成長。該領域最新的創新研究例子包括西班牙 IMIM（德爾馬醫院醫學研究所）研究人員於 2022 年在《歐洲放射學》上發表的一項研究，該研究使用 MRI 技術來可視化病變，其中包括使用造影增強乳腺X 光檢查引導乳房切片。

COVID-19大流行乳癌粗針穿刺切片市場帶來了挑戰，也帶來了新的機會。不必要的程序延誤導致診斷率降低並減少了對粗針穿刺切片的需求。然而，疫情凸顯了早期檢測的重要性，迫使醫療保健提供者優先考慮篩檢和切片檢查，導致需求回升。

粗針穿刺切片市場報告亮點

  • 從技術角度來看，超音波乳房切片領域由於其在疾病診斷方面優於其他切片檢查技術，將在 2022 年佔據市場主導地位。此外，技術進步的不斷進步預計也將加速該行業的成長。
  • 按最終用途分類，醫院和診斷實驗室產業在 2022 年佔據最大的市場佔有率。這是由於醫院擴大採用乳癌切片檢查設備以及對新診斷技術的需求不斷增加。
  • 由於其高度發展的醫療基礎設施和技術先進的公司的存在，北美在 2022 年將在市場中佔據強大的區域地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢及展望
  • 市場促進因素
    • 乳癌發生率增加
    • 影像和切片檢查技術的進步
    • 人們對微創手術的興趣日益濃厚
  • 市場約束
    • 粗針穿刺切片手術成本高
    • 專業知識和培訓有限
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章科技業務分析

  • 粗針穿刺切片市場：技術變化分析
  • 基於 MRI 的乳房切片
    • 基於 MRI 的乳房切片市場，2018-2030 年
  • 超音波乳房切片
    • 超音波乳房切片市場，2018-2030
  • 基於乳房X光檢查（立體定位）的乳房切片
    • 乳房X光攝影底座
  • 基於 CT 的乳房切片
    • 基於 CT 的乳房切片市場，2018-2030 年
  • 其他基於圖像的乳房切片
    • 其他基於影像的乳房切片市場，2018-2030

第5章 最終用途業務分析

  • 粗針穿刺切片市場：最終用途變化分析
  • 醫院/檢測機構
    • 醫院和實驗室市場，2018-2030
  • 製藥和生物技術公司
    • 製藥和生物技術公司、市場，2018-2030
  • 學術/研究機構
    • 學術和研究機構市場，2018-2030

第6章 區域業務分析

  • 2022年及2030年粗針穿刺切片市場佔有率（按地區）
  • 北美洲
    • SWOT分析
    • 北美粗針穿刺切片，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 歐洲乳癌粗針穿刺切片市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 亞太地區粗針穿刺切片，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲粗針穿刺切片，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • SWOT分析
    • 中東和非洲粗針穿刺切片，2018-2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭形勢

  • 公司分類
  • 策略規劃
  • 2022 年公司市場佔有率分析
  • 公司簡介/名單
    • Intact Medical Corporation.
    • Ethicon Surgical Technologies
    • Gallini SRL
    • Leica Biosystems Nussloch GmbH
    • Hologic, Inc.
    • Argon Medical Devices
    • Encapsule Medical Devices LLC
    • Cook Medical Incorporated
    • Becton, Dickinson and Company
    • CR Bard, Inc.
Product Code: GVR-4-68040-161-0

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

  • By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.
  • By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.
  • North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective 2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Drivers
    • 3.4.1. Growing prevalence of breast cancer
    • 3.4.2. Advancement in imaging technologies and biopsy techniques
    • 3.4.3. Rising inclination towards minimally invasive procedures
  • 3.5. Market Restraint
    • 3.5.1. High cost of core needle biopsy procedures
    • 3.5.2. Limited expertise and training
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Breast Cancer Core Needle Biopsy Market: Technology Movement Analysis
  • 4.2. MRI-Based Breast Biopsy
    • 4.2.1. MRI-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.3. Fermentation Ultrasound-Based Breast Biopsy
    • 4.3.1. Ultrasound-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.4. Mammography-Based (Stereotactic) Breast Biopsy
    • 4.4.1. Mammography-Based (Stereotactic) Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.5. CT-Based Breast Biopsy
    • 4.5.1. CT-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.6. Other Image-Based Breast Biopsy
    • 4.6.1. Other Image-Based Breast Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. Breast Cancer Core Needle Biopsy Market: End-use Movement Analysis
  • 5.2. Hospitals & Diagnostic Laboratories
    • 5.2.1. Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 5.3. Pharmaceutical & Biotechnology companies
    • 5.3.1. Pharmaceutical & Biotechnology Companies, Market, 2018 - 2030 (USD Million)
  • 5.4. Academic & Research Institutes
    • 5.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Breast Cancer Core Needle Biopsy Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. U.S. Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Canada Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. SWOT Analysis
    • 6.3.2. Europe Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. UK Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Germany Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. France Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Italy Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Spain Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Denmark Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Sweden Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Norway Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. SWOT Analysis
    • 6.4.2. Asia Pacific Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Japan Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. China Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. India Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Australia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Thailand Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. South Korea Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Brazil Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Mexico Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Argentina Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. South Africa Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Saudi Arabia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. UAE Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Kuwait Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. Intact Medical Corporation.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Ethicon Surgical Technologies
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Gallini SRL
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Leica Biosystems Nussloch GmbH
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Hologic, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Argon Medical Devices
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Encapsule Medical Devices LLC
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Cook Medical Incorporated
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Becton, Dickinson and Company
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. C.R. Bard, Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 15 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 16 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 19 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 20 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 22 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 24 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 26 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 28 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 30 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 35 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 36 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 37 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 38 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 39 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 41 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 43 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 44 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 45 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 47 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 48 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 50 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 52 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
  • Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 breast cancer core needle biopsy market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global breast cancer core needle biopsy market: Technology movement analysis
  • Fig. 16 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 17 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 18 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 19 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 20 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 21 Global breast cancer core needle biopsy market: End use movement analysis
  • Fig. 22 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
  • Fig. 23 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 24 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional outlook, 2022 & 2030
  • Fig. 27 Global breast cancer core needle biopsy market: Region movement analysis
  • Fig. 28 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)